September 25, 2026: Morgan Lewis advised Biolevate, a French AI company dedicated to life sciences, in connection with its €30 million (approximately $34.1 million) Series A funding round. The round was co-led by RAISE France, the investment vehicle of entrepreneur Aymar Hénin, and Orange Ventures, with participation from the MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures
This round follows the company’s €6 million (approximately $6.8 million) seed round in November 2024, which was led by EQT Ventures.
Founded in Paris by a team of former Dataiku engineers and AI researchers, Biolevate develops an agentic AI platform spanning the full life sciences value chain, including research, clinical trials, health technology assessments, regulatory dossiers, and drug discovery and development.
The new funding will enable Biolevate to strengthen its product capabilities and accelerate its international expansion, including the opening of a Boston office.
The Morgan Lewis team advising Biolevate included partner Sébastien Pontillo, associate Thomas Maincent, and jurist Carole Ruggiu on the corporate aspects, and partner Mathilde Carle on IP matters.
